Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: May 27, 2011

Premium

Adarza Biosystems this week appointed Heiner Dreismann and James Senall to its board of directors.

Dreismann was previously the CEO of Roche Molecular Systems and held several senior positions at Roche Diagnostics before that.

Senall is the president of High Tech Rochester, an Adarza shareholder, and is director of the Rochester Angel Network. Previously, he was managing director of business development at Greater Rochester Enterprise.


ACS Biomarker this week named Heico Breek as its CEO.

Previously, he was CEO of cardiovascular testing company Cavadis, as well as chief commercial officer at TiGenix and a general manager at Aventis.


Venture capitalist Peter Thiel this week announced the appointment of 24 Thiel fellows, each of whom will receive $100,000 over two years to pursue innovative scientific and technical projects. Among the awardees is Alexander Kiselev, whose project is to develop an inexpensive HPLC system.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.